An open study of SAMe as an adjunct to SSRI's in the treatment of MDD
Are you currently taking an antidepressant yet still experiencing symptoms of depression? The Depression Clinical and Research Program at Massachusetts General Hospital is currently studying whether adding Oral S-Adenosyl Methionine (SAMe) Selective Serotonin Reuptake inhibitor (SSRIs) antidepressants (such as Lexapro, Celexa, Prozac, Paxil, Zoloft) or venlafaxine (Effexor XR) for the treatment of depression enhances the efficacy of the SSRIs. SAMe is a naturally occurring substance found throughout the human body and is thought to enhance the effectiveness of antidepressants such as the SSRIs. The research study lasts for 8 weeks and involves weekly visits at our clinic in Boston. If you participate you would remain on your current SSRI dose throughout the study and will be randomly assigned to either 800mg of SAMe or placebo. Patients receiving SAMe will increase to 1600mg of SAMe after 2 weeks. Patients assigned to the placebo group will remain on placebo for the entire study. After the study ends, participants receive an additional 3 months of follow-up care in our clinic at no cost.
If interested please contact Juliana Smith at
617-724-2936 or jsmith44@partners.org.
We initiate new studies regularly, so please contact us for additional information.